Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3681770 | 1.00 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2TP53KMT2AMEN1 | |
| Trifluoroacetic Acid SCHEMBL3681762 | 0.94 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2TP53KMT2AMEN1 | |
| SCHEMBL13409971 | 0.92 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2TP53KMT2AMEN1 | |
| SCHEMBL3681769 | 0.86 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2TP53KMT2AMEN1 | |
| SCHEMBL14822999 | 0.81 | SMN1; SMN2 (0.59) | ALDH1A1SMN1; SMN2TP53KMT2AMEN1 | |
| Trifluoroacetic Acid SCHEMBL3682673 | 0.78 | S1PR1 (0.40) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3682670 | 0.78 | S1PR1 (0.40) | ALDH1A1 | |
| SCHEMBL13444465 | 0.78 | HPGD (0.43) | ALDH1A1SMN1; SMN2TP53KMT2AMEN1 | |
| Trifluoroacetic Acid SCHEMBL3688864 | 0.78 | POLB (0.32) | ALDH1A1POLB | |
| Trifluoroacetic Acid SCHEMBL3688859 | 0.78 | POLB (0.32) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | claimed |
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | ALDH1A1 236/4885SMN1; SMN2 1205/4885TP53 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.